Lyell Immunopharma (LYEL) Cash & Equivalents (2020 - 2026)

Lyell Immunopharma has reported Cash & Equivalents for 7 years, with the latest figure at $90.8 million in Q1 2026.

• Quarterly Cash & Equivalents fell 24.56% year-over-year to $90.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $90.8 million (down 24.56% YoY) and the FY2025 annual result came in at $60.2 million, down 43.01% from the prior year.
• Cash & Equivalents climbed to $90.8 million in Q1 2026 per LYEL's latest filing, from $60.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $286.2 million in Q3 2023 and troughed at $60.2 million in Q4 2025.
• A 5-year average of $140.7 million and a median of $123.6 million in 2022 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 70.44% in 2022, then soared 146.08% in 2023.
• Over 5 years, Cash & Equivalents stood at $123.6 million in 2022, then rose by 17.88% to $145.6 million in 2023, then dropped by 27.5% to $105.6 million in 2024, then slumped by 43.01% to $60.2 million in 2025, then soared by 50.83% to $90.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $90.8 million, $60.2 million, and $123.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.